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responsibility of XAbstract A selective, sensitive and high throughput liquid chromatography-tandem mass spectro-
metry (LC–ESI–MS/MS) method has been developed for separation and quantiﬁcation of
metoprolol enantiomers on a chiral Lux Amylose-2 (250 mm 4.6 mm, 5 mm) column. Solid phase
extraction of (S)-()- and (R)-(þ)-metoprolol and rac-metoprolol-d6 as an internal standard (IS)
was achieved on Lichrosep DVB HL cartridges employing 200 mL human plasma. Both the
analytes were chromatographically separated with a resolution factor of 2.24 using 15 mM
ammonium acetate in water, pH 5.0 and 0.1% (v/v) diethyl amine in acetonitrile (50:50, v/v) as
the mobile phase within 7.0 min. The precursor-product ion transitions for the enantiomers and
IS were monitored in the multiple reaction monitoring and positive ionization mode. The method
was validated over the concentration range of 0.500–500 ng/mL for both the enantiomers. Matrix
effect was assessed by post-column analyte infusion experiment and the mean extraction recovery
was greater than 94.0% for both the enantiomers at all quality control levels. The stability of
analytes was evaluated in plasma and whole blood under different storage conditions. The method
was successfully applied to a clinical study in 14 healthy volunteers after oral administration of
200 mg metoprolol tablet under fasting conditions. The assay reproducibility is shown by reanalysis
of 68 incurred samples. The suitability of the developed method was assessed in comparison withersity. Production and hosting by Elsevier B.V. All rights reserved.
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Enantiomeric study of drugs and/or its metabolites is of
growing interest in the ﬁeld of pharmaceutical and biomedical
analysis. b-blockers or b-adrenergic blocking agents are one of
the most explored pharmaceuticals for their stereochemical
impact on pharmacodynamics and pharmacokinetics. Major-
ity of b-blockers are marketed as racemic mixtures and hence
enantiomeric analysis in biological ﬂuids is essential to under-
stand their stereoselective implications, therapeutic use and
also in toxicological studies [1,2].
Metoprolol, a selective b-adrenoceptor antagonist, is used
in clinical practice in the racemic form for the treatment of
hypertension, angina pectoris and for several other cardiovas-
cular diseases [3–5]. The (S)-()-metoprolol has signiﬁcantly
higher b-adrenergic receptor afﬁnity (about 500-fold) com-
pared to its (R)-(þ)-antipode. In humans, the absorption of
metoprolol is rapid and complete. Plasma levels after oral
administration are almost 50% of levels attained following
intravenous administration, indicating 50% ﬁrst-pass meta-
bolism. A small fraction of the drug (12%) is bound to
human serum albumin and has a plasma half-life of 3–7 h. It is
primarily metabolized by CYP2D6 enzymes and exhibits
stereoselective metabolism that is essentially dependent on
oxidation phenotype. The three principal metabolic pathways
of metoprolol include (a) O-dealkylation to give O-desmethyl
metoprolol, which undergoes rapid oxidation to form an acid
metabolite, (b) a-hydroxylation to form a-hydroxy metoprolol
and (c) oxidative deamination to give N-dealkyl metoprolol.
About 85% of the administered drug is excreted in the urine as
metabolites, along with small amounts of unchanged parent
drug (less than 5%). The stereoselectivity in metoprolol
pharmacokinetics is observed with higher plasma concentra-
tion of (S)-()-metoprolol (S/R-metoprolol ratio 41) and
higher renal excretion of (R)-(þ)-metoprolol in healthy volun-
teers and hypertensive patients after oral dose of rac-meto-
prolol [6,7].
Numerous methods have been developed for enantioselec-
tive determination of metoprolol in biological samples using
different analytical techniques, such as capillary electrophor-
esis [8], GC–MS [9], HPLC with UV [10] and ﬂuorescence
detection [7,11–21], and LC–MS/MS [22,23]. These methods
can be characterized based on two different approaches
(i) direct methods, which involve use of chiral stationary
phase [7,10,11–14,17–23] and (ii) indirect methods, employing
derivatization with chiral reagents [9,15,16,19]. The choice of a
particular approach in bioanalysis is dictated by several
factors which include (a) the required assay sensitivity,
(b) ready availability, purity and stability of chiral derivatizing
agent, (c) efﬁciency and ease of derivatization, (d) suitable
chiral stationary phase, (e) simple and easy optimization of
chromatographic conditions and (f) overall analysis time
(extraction and chromatography). This is speciﬁcally intended
to facilitate application of the method in routine analysis of
real samples. Lanchote et al. [19] have compared directenantioselective separation of metoprolol enantiomers on
chiral stationary phase (Chiralpak AD and Chiralcel OD-H
columns) and indirect separation based on the formation of
diastereomeric derivatives with S-()-menthyl chloroformate
by HPLC. They concluded that the direct method with
Chiralpak AD was more sensitive compared to the indirect
approach, although both the methods demonstrated inter-
changeable use in the pharmacokinetic investigation. Mistry
et al. [20] carried out a stereoselective HPLC-ﬂuorescence
assay for the enantiomers of metoprolol and diastereoisomers
of its hydroxyl metabolite on Chirobiotic T bonded phase
column. The analytes were extracted from 1.0 mL plasma
sample by solid phase extraction (SPE) and the calibration
curve was established from 0.5 to 50 ng/mL for metoprolol
enantiomers. So far very few LC–MS/MS based methods are
available in literature for the analysis of metoprolol enantio-
mers in biological matrices. Jensen et al. [22] developed and
validated a stereoselective LC–MS/MS assay using Chirobio-
tic T column for quantiﬁcation of S- and R-metoprolol in
human plasma. The linear dynamic range was established
from 0.5 to 50 ng/mL and the run time for the method was
11.0 min. A human dried blood spot (DBS) sampling with
LC–MS/MS for enantioselective determination of metoprolol
and its metabolite has also been described [23]. This is a highly
rapid method (3.0 min); however, the sensitivity of the method
was 2.5 ng/mL. A detailed comparative summary of different
chromatographic methods developed for metoprolol enantio-
mers in biological samples is presented in Table 1.
The objective of the present study was to separate both the
isomers chromatographically and to develop a simple and
reliable LC–ESI–MS/MS method based on direct approach
for their quantitation in human plasma. The proposed method
exhibited superior performance in terms of sensitivity, dynamic
concentration range, selectivity, ruggedness and efﬁciency
(7.0 min per sample) due to cleaner extracts with a simple and
straight forward sample extraction protocol. It ensured the
estimation of both the isomers up to 24 h with desired accuracy
and precision to support a bioequivalence study in healthy
Indian volunteers. Additionally, this is the ﬁrst report on
successful demonstration of assay reproducibility through
incurred sample reanalysis for metoprolol enantiomers.2. Experimental
2.1. Chemicals and materials
Reference standards of S-()-metoprolol (99.0%) and R-(þ)-
metoprolol (99.0%) were purchased from Toronto Research
Chemicals Inc. (Ontario, Canada), while rac-metoprolol-d6
(99.6%) used as an internal standard (IS) was from TLC
Pharmachem Inc. (Ontario, Canada). HPLC grade methanol
and acetonitrile were obtained from Mallinckrodt Baker S.A.
de C.V. (Ecatepec, Mexico). Analytical reagent grade glacial
acetic acid, formic acid, sodium hydroxide, ammonium
Table 1 Comparative summary of chromatographic methods developed for S-()-metoprolol and R-(þ)-metoprolol in biological matrices.
Methods Technique; column Matrix;
sample
volume (mL)
Sample preparation Internal
standard
Linearity
(ng/mL)
Run time
(min)
Application; incurred sample
reanalysis
Ref.
Direct
methods—
using chiral
columns
HPLC-ﬂuorescence (excitation-229 nm,
emission-298 nm); Chiralpak AD
(250 mm 4.5 mm, 10.0 mm)
Human
plasma/
urine; 1000/
100
LC-18 SPE for plasma and LLE for
urine with dichloromethane-
di isopropyl ether in the presence of
1.0 M NaOH
NR 10–100 in
plasma,
250–
25000 in
urine
N.R. Steady-state
pharmacokinetics of
metoprolol in 10 hypertensive
patients; NR
[7]
HPLC-UVa (225 nm); CelluCoat
(250 mm 4.6 mm, 5.0 mm)
Human
plasma;
5000
SPE on Sep-Pak C18 Cartridges NR NR 30.0 Study of plasma-protein
binding along with 3 other b-
blockers; NR
[10]
HPLC-ﬂuorescence (excitation-228/
272 nm, emission-306 nm); Chiral-AGP
(100 mm 4.0 mm, 5.0 mm)
Human
plasma;
1000
LLE with dichloromethane-diethyl
ether in the presence of 1.0 M
NaOH
2-dehydroxy
metoprolol
0.5–200 20.0 Pharmacokinetic study with
200 mg metoprolol in healthy
subjects; NR
[11]
HPLC-ﬂuorescence (excitation-275 nm,
emission-315 nm); Chiralcel OD
(250 mm 4.6 mm, 10.0 mm)
Human
serum; 1000
LLE with diethyl ether in the
presence of 2.0 M NaOH
Rac-
verapamil
12.5–400 15.0 Pharmacokinetic study with
200 mg metoprolol in healthy
subjects; NR
[12]
HPLC-ﬂuorescenceb (excitation-272 nm,
emission-306 nm); Chiralcel OD
(250 mm 4.6 mm, 5.0 mm)
Human/dog
plasma or
urine; 1000
LLE with diethyl ether in the
presence of 1.0 M NaOH
(S)-alprenolol 2.5–250 35.0 Pharmacokinetic study with
10 mg/kg metoprolol in dogs;
NR
[13]
HPLC-ﬂuorescence (excitation-220 nm,
emission-320 nm); Chiralcel OD
(250 mm 4.6 mm, 5.0 mm)
Human
plasma;
1000
SPE on octadecylsilane columns d-propranolol 20–400 40.0 Pharmacokinetic study with
200 mg metoprolol in a
healthy subject; NR
[14]
HPLC-ﬂuorescencec (excitation-276 nm,
emission-309 nm); Chiralcel OD
(250 mm 4.6 mm, 10.0 mm)
Human
urine; 400
LLE with dichloromethane in the
presence of 1.0 M Na2CO3
NR NR 12.0 Pharmacokinetic study with
100 mg metoprolol in healthy
subjects; NR
[17]
HPLC-ﬂuorescence (excitation-276 nm,
emission-309 nm); (I) Phenomenex silica
(250 mm 4.6 mm, 5.0 mm) and (II)
Chiralcel OD (250 mm 4.6 mm, 5.0 mm)
Human
urine; 1000
LLE with dichloromethane in the
presence of 1.0 M NaOH
Pindolol 100–2000 50.0 Pharmacokinetic study with
100 mg metoprolol in a
healthy subject; NR
[18]
HPLC-ﬂuorescence (excitation-229 nm,
emission-298 nm); (I) Chiralpak AD
(250 mm 4.6 mm, 5.0 mm) and (II)
Chiralcel OD-H (150 mm 4.6 mm,
5.0 mm)
Human
plasma;
1000
For column I: SPE on Supelclean
LC-18; For column II: LLE with
dichloromethane-diisopropyl ether
in the presence of 1.0 M NaOH
NR 10–500
for the
column I
and II
10.0 for
column I
and 20.0
for column
II
Kinetic disposition study
with 200 mg metoprolol in a
healthy subject; NR
[19]
HPLC-ﬂuorescenced (excitation-225 nm,
emission-310 nm); Chirobiotic T bonded
phase (250 mm 4.6 mm, 5.0 mm)
Human
plasma;1000
SPE on silica bonded with ethyl
group
Rac-atenolol 0.5–100 15.0 Bioavailability study with
100 mg metoprolol in healthy
subjects; NR
[20]
HPLC-ﬂuorescencec (excitation-229 nm,
emission-298 nm); Chiralpak AD
(250 mm 4.6 mm, 5.0 mm)
Rat plasma;
1000
LLE with dichloromethane-
diisopropyl ether in the presence of
1.0 M NaOH
NR 10–250 30.0 Pharmacokinetic study with
15 mg/kg of metoprolol in
male Wistar rats; NR
[21]
LC–MS/MS; Chiral ASTEC Chirobiotic T
(250 mm 4.6 mm, 5.0 mm)
Human
plasma; 900
LLE with ethyl acetate in the
presence of 1.0 M NaOH
Rac-
propranolol
0.5–50 11.0 Pharmacokinetic study with
190 mg and 47.5 mg
metoprolol in patients; NR
[22]
LC–MS/MSe; Chiral-cellobiohydrolase
(100 mm 3.0 mm, 5.0 mm)
Spotting on Whatman FTA
DMPK-A cards followed by LLE
2.5–2500 3.0 [23]
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Table 1 (continued )
Methods Technique; column Matrix;
sample
volume (mL)
Sample preparation Internal
standard
Linearity
(ng/mL)
Run time
(min)
Application; incurred sample
reanalysis
Ref.
Dried blood
spots
(DBS); 20
with ethyl acetate in the presence
of 2% NaOH
Rac-
metoprolol-
d7
Comparison of developed
DBS assay with a plasma
assay; NR
LC–MS/MS; Lux Amylose-2
(250 mm 4.6 mm, 5.0 mm)
Human
plasma;200
SPE on LiChrosep DVB HL
cartridges
Rac-
metoprolol-
d6
0.5–500 7.0 Bioequivalence study with
200 mg metoprolol in 14
healthy subjects; % change
varied from -13.0 % to 13.0
%
PW
Indirect
methods—-
via
derivatiza-
tion on
achiral
columns
GC–MS; Capillary column HP-5 MS
(30 m 0.25 mm 0.25 mm ﬁlm thickness)
Human
urine; 1000
LLE with hexane-butanol in the
presence of 0.05 M HCl followed by
derivatization with ()-MTPA-Cl,
using MSTFA
Bisoprolol 100–4000 25.0 Pharmacokinetic study with
100 mg metoprolol in a
healthy subject; NR
[9]
HPLC-ﬂuorescence (excitation-220 nm, no
emission ﬁlter); Stainless steel
(250 mm 4.6 mm, 5.0 mm)
Human
plasma;
1000
LLE with chloroform in the
presence of 0.1 M NaOH followed
by derivatization with NEIC
rac-
propranolol
5.0–500 30.0 Pharmacokinetic study with
100 mg metoprolol in a
healthy subject; NR
[15]
HPLC-ﬂuorescencef (excitation-223 nm,
emission-340 nm); Hypersil 5 C18
(250 mm 4.6 mm, 5.0 mm)
Human
urine; 2000
LLE with ethyl acetate in the
presence of 2.0 M K2CO3 followed
by derivatization with S-()-MCF
Rac-toliprolol 375–
11250
30.0 Excretion rate and
stereoselective metabolism in
young and old subjects; NR
[16]
HPLC-ﬂuorescence (excitation-223 nm,
emission-340 nm); Lichrospher RP-8
(125 mm 4.0 mm, 5.0 mm)
Human
plasma;
1000
LLE with dichloromethane-
diisopropyl ether in presence of
1.0 M NaOH followed by
derivatization with S-()-MCF
NR 10–500 15.0 Kinetic disposition study
with 200 mg metoprolol in a
healthy subject; NR
[19]
LLE: liquid-liquid extraction; SPE: solid-phase extraction; NR: not reported; PW: present work; ()-MTPA-Cl: ()-a-methoxy-a-(triﬂuoromethyl)-phenylacetyl chloride; MSTFA: N-methyl-N-
(trimethylsilyl)triﬂuoroacetamide; NEIC: (S)-(þ)-1-(1-naphthyl)ethyl isocyanate; S-()-MCF: S-()-menthyl chloro formate
aAlong with carazolol, oxprenolol and alprenolol;
bAlong with four enantiomeric forms of a-hydroxy metoprolol;
cAlong with the enantiomers of its metabolite O-desmethyl metoprolol and a-hydroxy metoprolol;
dAlong with the diastereoisomers of a-hydroxy metoprolol;
eAlong with enantiomers of oxazepam, bupivacaine and terbutaline;
fAlong with its major acidic metabolite;
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Enantiomeric determination of metoprolol by chiral LC–MS/MS 67formate, ammonium acetate, ammonium triﬂuoroacetate,
ammonia solution (30%), diethyl amine and LiChrosep
DVB HL cartridges (30 mg, 1cc) were obtained from Merck
Specialties Pvt. Ltd. (Mumbai, India). Water used in the entire
analysis was prepared from Milli-Q water puriﬁcation system
procured from Millipore (Bangalore, India). Blank human
plasma was procured from Supratech Micropath (Ahmeda-
bad, India) and was stored at 20 1C until use.
2.2. Liquid chromatography and mass spectrometric
conditions
A Shimadzu LC-VP HPLC system (Kyoto, Japan) consisting
of LC-20AD prominence pump, SIL-HTc autosampler, CTO
10 ASvp column oven and a DGU-20 A3 degasser was used
for setting the reverse-phase liquid chromatographic condi-
tions. The separation of analytes and IS was performed on a
Phenomenex Lux Amylose-2 (250 mm 4.6 mm, 5 mm) col-
umn and was maintained at 35 1C in a column oven. The
mobile phase consisted of 15 mM ammonium acetate, pH 5.0
adjusted with acetic acid and 0.1% (v/v) diethyl amine in
acetonitrile (50:50, v/v). For isocratic elution, the ﬂow rate of
the mobile phase was kept at 1.0 mL/min with 80% ﬂow
splitting; ﬂow directed to the ion spray interface was equiva-
lent to 200 mL/min. The autosampler temperature was main-
tained at 5 1C and the pressure of the system was 1500 psi.
Ionization and detection of analytes and IS was carried out
on a triple quadrupole mass spectrometer, MDS SCIEX API-
4000 (Toronto, Canada), equipped with electrospray ionization
and operating in positive ionization mode. Quantitation was
performed using multiple reaction monitoring (MRM) mode to
monitor precursor-product ion transitions of m/z 268.3-
116.3 for S-()-metoprolol and R-(þ)-metoprolol and m/z
274.2-122.2 for IS respectively. The source dependent para-
meters maintained for the analytes and IS were Gas 1
(Nebulizer gas): 30 psig; ion spray voltage (ISV): 5500 V, turbo
heater temperature: 400 1C; entrance potential: 10 V; collisional
activation dissociation (CAD): 5 psig and curtain gas, nitrogen:
10 psig. The optimum values for compound dependent para-
meters like declustering potential, collision energy and cell exit
potential were set at 70, 26 and 10 eV respectively for both the
analytes and IS. Analyst classic software version 1.4.2 was used
to control all parameters of LC and MS.
2.3. Standard stock, calibration standards and quality control
sample preparation
The standard stock solution of 1.0 mg/mL for S-()-metoprolol
and R-(þ)-metoprolol respectively was prepared by dissolving
requisite amount in methanol. Calibration standards and
quality control (QC) samples were prepared by spiking (2%
of total volume of blank plasma) blank plasma with the stock
solution. Calibration curve standards were made at 0.500, 1.00,
2.00, 4.00, 10.0, 20.0, 50.0, 100, 250 and 500 ng/mL concentra-
tions respectively while QC samples were prepared at ﬁve levels,
400 ng/mL (HQC, high quality control), 200/30.0 ng/mL
(MQC-1/2, medium quality control) and 1.50 ng/mL (LQC,
low quality control) for both the analytes respectively. Stock
solution (1.0 mg/mL) of the IS was prepared by dissolving
requisite amount of rac-metoprolol-d6 in methanol. An aliquot
of 25 mL of this solution was further diluted to 25.0 mL inmethanol to obtain a working solution of 1.0 mg/mL. All the
solutions (standard stock, calibration standards and quality
control samples) were stored at 2–8 1C until use.
2.4. Sample extraction protocols
Prior to analysis, all frozen subject samples, calibration
standards and quality control samples were thawed and
allowed to equilibrate at room temperature for 30 min. To
an aliquot of 200 mL of spiked plasma sample, 50 mL internal
standard solution and 50 mL of 0.1 M sodium hydroxide in
water was added and vortex mixed for 20 s. The samples were
then centrifuged at 3200 g for 2 min at 10 1C and loaded on
LiChroseps DVB-HL (1cc, 30 mg) extraction cartridges,
which were preconditioned with 1.0 mL of methanol followed
by 1.0 mL of water. Washing of the samples was done with
1.0 mL water, followed by 1 mL of methanol: 2% (v/v)
ammonia solution in water (30:70, v/v). The analytes and
ISs were eluted using 500 mL, of 2% (v/v) acetic acid in
methanol and collected in pre-labeled vials. The eluates were
evaporated to dryness under gentle stream of nitrogen (20 psi)
at 40 1C. The dried samples were reconstituted with 100 mL of
the mobile phase, vortex-mixed for 30 s and 10 mL was used
for injection in the chromatographic system.
2.5. Method validation procedures
The method validation was performed as per the USFDA
guidelines [24]. System suitability experiment was performed by
injecting six consecutive injections of aqueous standard mixture
of S-()-metoprolol and R-(þ)-metoprolol (at MQC-1) and IS
(1.0 mg/mL) at the start of each batch during method valida-
tion. System performance was studied by injecting one
extracted blank (without analyte and IS) and one ULOQ &
LLOQ sample with IS at the beginning of each analytical batch
and before re-injecting any sample during method validation.
Carry over effect of autosampler was checked to verify any
carryover of analyte at the start and at the end of each batch.
The sequence of injection for this experiment was, extracted
blank plasma-ULOQ sample-extracted blank plasma-
LLOQ sample-extracted blank plasma.
The selectivity of the method towards endogenous plasma
matrix components was assessed in ten different batches of
plasma, of which, seven were normal K3EDTA plasma and one
each of lipidemic, haemolysed and heparinized plasma. The
selectivity of the method towards commonly used medications
in human volunteers was done for acetaminophen, cetirizine,
domperidone, ranitidine, diclofenac and ibuprofen in six
different batches of plasma having K3EDTA as anticoagulant.
Their stock solutions (1.00 mg/mL) were prepared by dissol-
ving requisite amount in methanol. Further, their working
solutions (500 ng/mL) were prepared in methanol:water (50:50,
v/v) spiked in plasma and analyzed under the same SPE
conditions at LQC and HQC levels in triplicate.
The linearity of the method was determined by analysis of
ﬁve linearity curves containing nine non-zero concentrations.
The area ratio responses (analyte/IS) were obtained from
MRM for regression analysis. Each calibration curve was
analyzed individually by least square weighted (1/x2) linear
regression. The lowest standard on the calibration curve was
accepted as the lower limit of quantitation (LLOQ), if the
P. Sharma et al.68analyte response was at least ten times more than that of drug-
free (blank) extracted plasma.
For determining the intra-batch accuracy and precision,
plasma samples of S-()-metoprolol and R-(þ)-metoprolol
were analyzed in six replicates of LLOQ QC, LQC, MQC-2/1
and HQC samples along with a calibration curve in a single
day. The inter-batch accuracy and precision were assessed by
analyzing ﬁve precision and accuracy batches on three con-
secutive validation days. The precision (% CV) at each
concentration level from the nominal concentration should
not be greater than 15%.
Qualitative ion suppression/enhancement effects on the
MRM LC–MS/MS sensitivity were evaluated by post-column
analyte infusion experiment. A standard solution containing
the analytes (at MQC level) and IS was infused post-column
via a ‘T’ connector into the mobile phase at 10 mL/min
employing the infusion pump. Aliquots of 10 mL of extracted
control plasma were then injected into the column by the
autosampler and MRM LC–MS/MS chromatograms were
acquired for the analytes and IS.
The relative recovery, absolute matrix effect and process
efﬁciency were evaluated at HQC, MQC1/2 and LQC levels in
six replicates. Relative recovery for the analytes and IS was
calculated by comparing the mean area response of extracted
samples (spiked before extraction) to that of unextracted
samples (spiked after extraction) at each QC level. Absolute
matrix effect was assessed by comparing the mean area
response of unextracted samples (spiked after extraction) with
the mean area of neat standard solutions. The overall ‘process
efﬁciency’ was calculated by comparing the mean area
response of extracted samples (spiked before extraction) to
that of neat standard solutions. The assessment of relative
matrix effect was based on the calculation of precision (% CV)
values for slopes of calibration lines from eight plasma lots
(including heparinized, haemolysed and lipidemic). For a
method to be practically free from relative matrix effect the
% CV should not exceed 3–4% [25].
All stability results were examined by measuring the
response (area ratio) of stability samples against freshly
prepared comparison standards with identical concentration.
Stock solution of the analytes and IS was checked for short
term stability at room temperature and long term stability at
5 1C. The solutions were considered stable if the deviation
from nominal value was within 710.0%. Autosampler stabi-
lity (wet extract), bench top (at room temperature), dry extract
(at 20 1C), and freeze-thaw stability (at 20 1C and 70 1C)
were performed at LQC and HQC using six replicates at each
level. Similarly, the long term stability of spiked plasma
samples stored at 20 1C and 70 1C was also studied at
both these levels. Whole blood stability was also determined to
ascertain any enzymatic degradation by spiking blood samples
with analytes at both the QC levels at room temperature up to
2.0 h and in wet ice batch maintained below 10 1C.
To establish the ruggedness of the proposed method, it was
performed on two precision and accuracy batches. The ﬁrst
batch was analyzed on two different columns (same make but
different batch no.), while the second batch was analyzed by
two different analysts who were not part of method validation.
Dilution reliability was evaluated by preparing a spiked
standard at 900 ng/mL concentration of S-()-metoprolol
and R-(þ)-metoprolol respectively in the screened plasma.
The precision and accuracy at 1/2 (450 ng/mL) and 1/10th(90 ng/mL) dilution were determined by analyzing the samples
against freshly prepared calibration curve standards.
2.6. Bioequivalence study design and incurred sample
reanalysis
The proposed method was applied to quantify plasma enantio-
mer concentration for a bioequivalence study conducted in 14
healthy Indian subjects after oral administration of test (200 mg
metoprolol succinate extended release tablet, equivalent to
155.63 mg metoprolol from an Indian Pharmaceutical Company,
India) and reference (Selo-zoks, 200 metoprolol succinate
extended release tablet, equivalent to 155.63 mg metoprolol from
AstraZeneca, Denmark) formulations under fasting conditions.
The study was an open label, balanced, randomized single-dose,
two-treatment, two-sequence, two-period crossover study. The
primary target variables of the study were Cmax, AUC0–24, and
AUC0-inf, which were analyzed using the conﬁdence interval
approach. The secondary end points of the study included
AUC0–24/AUC0-inf, Tmax, Kel and t1/2. Each subject was judged
to be in good health through medical history, physical examina-
tion and routine laboratory tests. Written consent was taken
from all the subjects after informing them about the objectives
and possible risks involved in the study. The study was
conducted strictly in accordance with guidelines laid down by
International Conference on Harmonization and USFDA [26].
The subjects were fasted 10 h before administration of the drug
formulation. They were orally administered a single dose of test
and reference formulations after recommended wash out period
of 7 days with 200 mL of water. The blood samples were
collected in labeled K3EDTA-vacutainers at pre-dose time 0.00,
1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0,
9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0 and 24 h. Plasma was
separated by centrifugation and kept frozen at 20 1C till the
completion of study and then at 70 1C until analysis. During
the study, subjects had a standard diet while water intake was
unmonitored. The pharmacokinetic parameters of S-()-meto-
prolol and R-(þ)-metoprolol were estimated by non-
compartmental model using WinNonlin software version 5.2.1
(Pharsight Corporation, Sunnyvale, CA, USA). To determine
whether the test and reference formulations were pharmacoki-
netically equivalent, Cmax, AUC0–24, and AUC0-inf and their
ratios (test/reference) using log transformed data were assessed;
their means and 90% CIs were analyzed by using SASs software
version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
The assay reproducibility test was also conducted by
selection of 10% of total subject samples analyzed, which
included samples near the Cmax and the elimination phase in
the pharmacokinetic proﬁle of the enantiomers. The percent
change in the values, which were calculated using the follow-
ing formula, should not be more than 720% [27,28].
% Change¼ Repeat value2Initial value
Mean of repeat and initial values
 1003. Results and discussion
3.1. Method development
As evident from the available literature, bulk of the methods
reported on enantiomeric analysis of metoprolol is based on
Fig. 1 Product ion mass spectra of: (A) S-()-metoprolol (m/z 268.3-116.3, scan range 100–300 amu), (B) R-(þ)-metoprolol
(m/z 268.3-116.3, scan range 100–300 amu), and (C) Rac-metoprolol-d6, internal standard (m/z 274.2-122.2, scan range 100–300 amu) in
positive ionization mode.
Enantiomeric determination of metoprolol by chiral LC–MS/MS 69
Table 2 Mean relative recovery and absolute matrix effect of S-()-metoprolol and R-(þ)-metoprolol by LLE and SPE at
LQC level.
Extraction conditions Relative recovery
(%)
Absolute matrix effect (%)
S-isomer R-isomer S-isomer R-isomer
Methyl tert-butyl ether:ethyl acetate (70:30, v/v) in the presence of 1.0 M NaOH 56.5 52.1 63.5 62.2
Methyl tert-butyl ether in the presence of 1.0 M NaOH 78.2 80.6 83.3 87.1
Ethyl acetate:dichloromethane (50:50, v/v) in the presence of 1.0 M NaOH 83.5 85.1 89.1 90.3
Dichloromethane in the presence of 1.0 M NaOH 79.5 82.3 85.3 86.1
Dichloromethane:diethyl ether (50:50, v/v) in the presence of 1.0 M NaOH 84.5 85.1 88.2 89.5
SPE using sample pretreated with 0.1 M NaOH 94.5 95.9 102.8 102.4
P. Sharma et al.70direct analysis on chiral columns [7,10–14,17–23]. This is
apparently due to comparable or better assay sensitively [19]
without an additional derivatization step during sample
processing than indirect methods. Moreover, easy availability
of wide variety of stable and rugged chiral stationary phases
has further propelled their use in enantioselective analysis. All
ﬁve major classes of stationary phases including macrocyclic
glycopeptide [20,22], polysaccharide [10,12–14,17–19,21], pro-
tein [11,17,23], cyclodextrin [17] and Pirkle-type [17] have been
used in the separation and quantitation of metoprolol enan-
tiomers from biological samples with varying degree of
success. Moreover, these stationary phases can be used under
normal and reversed-phase conditions and also with modiﬁed
polar organic mobile phases, except the protein based sta-
tionary phase. Nevertheless, chiral columns coupled to mass
spectrometric (MS) detection warrant careful optimization of
mobile phase not only for enantiomeric resolution but also for
compatibility with the MS interface and adequate MS
response for assay sensitivity. In our effort to develop a
sensitive, selective, high throughput and rugged method, this
essential criterion was suitably optimized during method
development along with the extraction procedure.3.1.1. Mass spectrometry
The present study was conducted using ESI as the ionization
source in the positive ionization mode as it gave high intensity
for S-()-metoprolol, R-(þ)-metoprolol and IS due to the
presence of secondary amine which is easily protonated and a
good linearity in regression curves. Initially, the precursor and
product ions were optimized by infusing 500 ng/mL solutions
in the mass spectrometer between 100 and 300 mass range. Q1
MS full scan spectra for the analytes and IS essentially
contained protonated precursor [MþH]þ ions at m/z 268.3
and 274.2 respectively. The most abundant and consistent
product ions in Q3 MS spectra for the analytes and IS were
observed at m/z 116.3 and 122.2 respectively by applying
26 eV collision energy (Fig. 1). The product ion fragment at m/
z 116.3 for the analytes can be attributed to the substructure
with an isopropyl amine group. The source dependent and
compound dependent parameters were suitably optimized to
obtain a consistent and adequate response for the analytes. A
dwell time of 100 ms gave sufﬁcient sampling points to obtain
reproducible results for the analytes and IS and no cross talk
was found between their MRMs.3.1.2. Optimization of extraction procedure
All reported methodologies based on direct approach have
used either SPE [10,14,19,20] or liquid–liquid extraction (LLE)
in the presence of a base [7,11–13,17–19,21,22] for quantitative
recovery of analytes. As metoprolol is a basic drug (pka 9.7),
it can be readily converted to an unionized state with a base
for better extraction efﬁciency during LLE. Several solvent
systems such as dichloromethane [17,18], dichloromethane-
diisopropyl ether [7,19,21], diethyl ether [12,13],
dichloromethane-diethyl ether [11] and ethyl acetate [22] have
been used previously for LLE. Thus, both these conventional
techniques were tested for optimum recovery with minimum
matrix interference during method development trials. LLE
was tried in some of these solvents as well methyl tert-butyl
ether, while SPE was done on LiChrosep DVB HL cartridges.
The results obtained for different extraction trials are sum-
marized in Table 2. As evident, the results with SPE were
superior compared to LLE with minimum matrix interference
and thus was accepted in the present study. Further, use of 2%
(v/v) acetic acid in methanol during SPE elution ensured good
assay reproducibility and analyte recovery.3.1.3. Optimization of chromatographic conditions
Chromatographic resolution of S-()-metoprolol and R-(þ)-
metoprolol was initiated under isocratic conditions to obtain
adequate response, sharp peak shape and a short analysis time
on two polysaccharide based stationary phases namely Lux
Amylose-2 (250 mm  4.6 mm, 5 mm) and Chiralcels OD
(250 mm 4.6 mm, 5 mm) and one protein based Chiral-AGP
(250 mm 4.6 mm, 5 mm) columns. Different mobile phase
compositions (methanol/acetonitrile and aqueous), buffer
solutions (ammonium acetate/acetic acid, ammonium for-
mate/formic acid) and modiﬁer (diethyl amine) for basic
analytes were investigated to evaluate the impact on retention
and resolution of analyte enantiomers on the columns. Protein
based columns showed enantioselectively for broad spectrum
of analytes; however, can be used only under reversed-phase
conditions with limited proportion of organic solvent (gen-
erally less than 50%) in the mobile phase. Moreover, ionic
strength, pH, type and concentration of organic modiﬁers play
a signiﬁcant role in the retention and resolution on protein-
based phases [1]. Chiral-AGP column has been used pre-
viously by Persson et al. [11] with a mobile phase consisting of
phosphate buffer (pH 7.0) and acetonitrile under gradient
HPLC conditions. Similarly, Kim et al. [17] used a 20 mM
Fig. 2 Chromatograms of metoprolol enantiomers (m/z 268.3-
116.3) obtained on: (A) protein based Chiral-AGP (250 mm 4.6
mm, 5 mm), (S), (B) Chiralcels OD (250 mm 4.6 mm, 5 mm) and
(C) Lux Amylose-2 (250 mm 4.6 mm, 5 mm). Mobile phase for
column (A) 15 mM ammonium acetate, pH 5.0 adjusted with
acetic acid-0.1% diethyl amine in acetonitrile (70:30, v/v), for (B)
and (C) 15 mM ammonium acetate, pH 5.0 adjusted with acetic
acid-0.1% diethyl amine in acetonitrile (50:50, v/v).
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(Rs) of 1.79 for metoprolol enantiomers under isocratic
conditions. However, due to incompatibility of phosphate
buffer with MS detection, a combination of ammonium
acetate-acetic acid buffer (pH 5.0)-methanol/acetonitrile
(70:30, v/v) was tried initially under isocratic conditions.
Due to low organic solvent content the retention time for
the analytes was too long (16.0 min), with poor resolution
(Rs 0.2) between the enantiomers. Addition of 0.1% diethyl
amine in the mobile phase afforded a marginal increase in the
resolution (Rs 0.5) as shown in Fig. 2A. Thus, polysacchar-
ide based stationary phases, Chiralcel OD [cellulose tris(3,5-
dimethylphenylcarbamate)] and Lux Amylose-2 [amylose
tris(5-chloro-2-methylphenylcarbamate)] were tested which
can withstand polar organic mobile phase and thus assist in
shortening the retention times for analytes. Polysaccharide
based stationary phases can be used with normal mobile
phases consisting of alkane-alcohol mixture for HPLC appli-
cations. This combination along with modiﬁers such as diethyl
amine or octylamine has been well established for enantiose-
lective analysis of metoprolol on Chiralcel OD column
[12–14,17,18]. Nonetheless, use of an alkane in the mobile
phase is not worthwhile when coupling the column to APCI or
ESI source for MS detection due to its inﬂammable nature.
Thus, different volatile salts like ammonium acetate, ammo-
nium formate and ammonium triﬂuoroacetate along with
0.1% diethyl amine in acetonitrile/methanol were tested on
Chiralcel OD and Lux Amylose-2 columns. These salts
facilitate ionization and provide enhanced MS detection for
assay sensitivity. Both the columns offered adequate retention
and resolution of metoprolol enantiomers compared to Chiral-
AGP column using 15 mM ammonium acetate, pH 5.0
adjusted with acetic acid-0.1% diethyl amine in acetonitrile
(50:50, v/v) as the mobile phase (Fig. 2B and C). Nevertheless,
based on higher resolution, peak shape, shorter chromato-
graphic run time and superior response, Lux Amylose-2 was
selected for further study. Baseline separation (Rs, 2.24) of the
analytes was possible within 7.0 min, with a retention time of
4.79 and 5.63 min for S-()-metoprolol and R-(þ)-metoprolol
respectively. The efﬁciency of the Lux Amylose-2 column
expressed as the theoretical plate number was 2997 and 3170
for S-()-metoprolol and R-(þ)-metoprolol respectively with
a separation factor of (a)¼1.4. This helps in maintaining
column efﬁciency and extending its life time for more number
of injections. Further, the reproducibility of retention time for
both the analytes, expressed as % CV was r0.6% for more
than 100 injections on the same column. The deuterated
internal standard (rac-metoprolol-d6) used in the study had
similar chromatographic behavior and was quantitatively
extracted with the proposed extraction procedure. Also, there
was no effect of IS on analyte recovery, sensitivity or ion
suppression.
The representative MRM ion chromatograms in Fig. 3 of
extracted blank human plasma (double blank), blank plasma
fortiﬁed with IS, analytes at LLOQ and an actual subject
sample at 5.0 h demonstrate the selectivity of the method.
Based on the selectivity achieved in plasma samples and a
high signal to noise ratio (S/NZ75), it was possible to lower
the LLOQ down to 0.070 ng/mL; however, it was not
required based on the concentration of enantiomers found
in subject samples. None of the commonly used medications
by human volunteers (acetaminophen, cetirizine,domperidone, ranitidine, diclofenac and ibuprofen) inter-
fered in the determination of analytes. Moreover, due to
difference in their MRM transitions there was no interference
in the quantiﬁcation. The accuracy results were within 95.9–
102.7% for S-()-metoprolol and R-(þ)-metoprolol at both
the QC levels. The average matrix factor value calculated as
the response of post spiked sample/response of neat solution
in reconstitution solution at LLOQ level was between 1.02
and 1.04 for both the analytes, which indicates negligible
Fig. 3 MRM ion-chromatograms of: (A) double blank plasma (without IS), (B) blank plasma with rac-metoprolol-d6 (IS), (C) S-()-
metoprolol and R-(þ)-metoprolol at LLOQ level (m/z 268.3-116.3) and IS (m/z 274.2-122.2), and (D) real subject sample at 5.0 h after
administration of 200 mg extended release metoprolol tablet.
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experiment show no ion suppression or enhancement at the
retention time of S-()-metoprolol and R-(þ)-metoprololand IS (Fig. 4). Though signiﬁcant ion suppression was
observed around 1.0–1.5 min, nevertheless it did not interfere
in the quantitation of analytes.
Fig. 4 Post-column analyte infusion MRM LC–MS/MS chromatograms for: (A) S-()-metoprolol and R-(þ)-metoprolol (m/z 268.3-
116.3), and (B) Rac-metoprolol-d6 (m/z 274.2-122.2).
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The precision (% CV) in the measurement of retention time and
the response (area ratio) for system suitability test was observed
in the range of 0.05–0.34% and 0.32–1.54% respectively, while
the signal to noise ratio for system performance was Z75 for
both the enantiomers. Carry-over evaluation was performed in
each analytical run so as to ensure that it does not affect the
accuracy and the precision of the proposed method. As evident
from Fig. 5A–D, there was practically negligible carry-over
(r0.82%) during auto-sampler carryover experiment. All ﬁve
calibration lines for S-()-metoprolol and R-(þ)-metoprolol
were linear over the concentration range of 0.500–500 ng/mL.
The mean linear equation was y¼ (0.00587 0.0001)xþ
(0.001170.0001) and y¼(0.005970.0001)xþ(0.001170.0000)
for S-()-metoprolol and R-(þ)-metoprolol respectively, where
y is the peak area ratio of the analyte/IS and x the concentra-
tion of the analyte. The mean correlation coefﬁcient (r2) was
Z0.9987 for both the analytes.
The intra-batch and inter-batch precision and accuracy
values at ﬁve QC levels are shown in Table 3. The intra-
batch precision (% CV) and accuracy ranged from 1.2% to
3.6% and 94.7% to 105.3% respectively for both the
enantiomers. Similarly, for the inter-batch experiment,
the precision varied from 0.3% to 1.3% and the accuracy
was within 98.2–103.5% for both the analytes. The relative
recovery, absolute matrix effect and process efﬁciency data
for S-()-metoprolol and R-(þ)-metoprolol and IS are
presented in Table 4. The mean relative recovery for SPE
of the analytes was 496% across four QC levels. For IS,the mean extraction recovery was greater than 93%. The
absolute matrix effect values ranged from 100.6 to 103.2
for both the enantiomers. The coefﬁcient of variation (%
CV) of the slopes of calibration lines for relative matrix
effect in eight different plasma lots was r2.9 for both the
analytes (Table 5).
The stability of S-()-metoprolol and R-(þ)-metoprolol
was systematically evaluated in stock solutions and in plasma
samples under different storage conditions. Stock solutions
for short-term stability remained stable at room temperature
up to 7 h, and for minimum of 7 days at refrigerated
temperature of 5 1C for long term stability of both the
analytes and IS. S-()-metoprolol and R-(þ)-metoprolol in
control human plasma (bench top) at room temperature were
stable for at least 10 h at 25 1C and for minimum of ﬁve
freeze-thaw cycles. Spiked plasma samples stored at –20 1C
and –70 1C for long term stability experiment were found
stable for a minimum period of 326 days. For blood sample
stability the percentage change from comparison samples was
less than 1.2% at two QC levels. Autosampler stability and
dry extract stability of the analytes were determined up to
70 h without signiﬁcant drug loss. Different stability experi-
ments in plasma at two QC levels; with the values for percent
change are shown in Table 6.
For method ruggedness, the precision (% CV) and accu-
racy values for two different columns ranged from 0.6% to
3.6% and 96.5% to 104.8% respectively for both the analytes
at all QC levels. Similarly, for the experiment with different
analysts, the results for precision and accuracy were within
1.0%–3.6% and 96.4%–101.8% respectively. The dilution
Fig. 5 MRM ion-chromatograms for carry-over test of: (A) double blank plasma (without analyte and IS), (B) S-()-metoprolol and R-(þ)-
metoprolol at ULOQ level and IS, (C) double blank plasma (without analyte and IS) and (D) S-()-metoprolol and R-(þ)-metoprolol at LLOQ level
and IS.
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test to be carried out on higher analyte concentration above
ULOQ, which may be encountered during real subjectsample analysis. The precision for dilution integrity of 1/2
and 1/10th dilution was 1.2% and 0.8%, while the accuracy
results were 93.2% and 96.8% respectively.
Table 3 Intra-batch & inter-batch accuracy and precision for S-()-metoprolol and R-(þ)-metoprolol.
Nominal concentration
(ng/mL)
Intra-batch (n¼5; single batch) Inter-batch (n¼25; 5 from each batch)
Mean concentration
found (ng/mL)
Accuracy (%) Precision (%) Mean concentration
found (ng/mL)
Accuracy (%) Precision (%)
S-()-metoprolol
400 421 105.3 1.9 411 102.8 0.5
200 209 104.5 1.3 207 103.5 0.5
30.0 30.8 102.7 1.2 30.2 100.7 0.5
1.50 1.53 102.0 3.6 1.49 99.3 1.3
0.500 0.491 98.2 3.3 0.493 98.6 1.1
R-(þ)-metoprolol
400 415 103.8 1.2 409 102.3 1.1
200 204 102.0 1.5 202 101.0 1.2
30.0 28.4 94.7 1.3 30.1 100.3 0.3
1.50 1.48 98.7 2.3 1.51 100.7 1.2
0.500 0.489 97.8 3.1 0.491 98.2 0.5
Table 4 Absolute matrix effect, relative recovery and process efﬁciency for S-()-metoprolol and R-(þ)-metoprolol.
Analyte Area response Absolute matrix
effect ðB=AÞ 
100 (Internal
standard)
Relative recovery
ðC=BÞ  100
(Internal standard)
Process efﬁciency
ðC=AÞ  100
(Internal
standard)
A, reconstitution
solution
(Precision, %)
B, spiked in
extracted blank
plasma
(Precision, %)
C, spiked before
extraction
(Precision, %)
HQC
S-()-
metoprolol
1860324 (5.0) 1870973 (1.8) 1815582 (4.7) 100.6 (95.2) 97.0 (92.5) 97.6 (88.1)
R-(þ)-
metoprolol
1913390 (5.4) 1941257 (2.4) 1911388 (7.1) 101.5 (101.4) 98.5 (91.8) 99.9 (93.1)
MQC1
S-()-
metoprolol
997723 (4.1) 1012560 (5.0) 987886 (2.5) 101.5 (97.9) 97.6 (89.7) 99.0 (87.8)
R-(þ)-
metoprolol
1031698 (3.5) 1055489 (6.2) 1017144 (3.4) 102.3 (101.2) 96.4 (91.7) 98.6 (92.8)
MQC2
S-()-
metoprolol
168005 (5.5) 171960 (5.1) 162838 (3.8) 102.4 (96.9) 94.7 (97.1) 96.9 (94.1)
R-(þ)-
metoprolol
167777 (5.6) 173124 (5.3) 168069 (4.0) 103.2 (102.4) 97.1 (91.2) 100.2 (93.4)
LQC
S-()-
metoprolol
8570 (4.7) 8812 (6.3) 8327 (5.2) 102.8 (94.4) 94.5 (94.6) 97.2 (88.9)
R-(þ)-
metoprolol
8620 (4.4) 8824 (7.5) 8462 (5.4) 102.4 (94.2) 95.9 (96.0) 98.2 (90.4)
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results
To the best of our knowledge there are no reports on the
pharmacokinetics/bioequivalence study of metoprolol enan-
tiomers in Indian subjects. The validated method was success-
fully used to quantify S-()-metoprolol and R-(þ)-metoprolol
concentration in human plasma samples after administration
of a 200 mg extended release metoprolol test and reference
formulations to 14 healthy Indian subjects. Fig. 6 shows the
plasma concentration vs. time proﬁle of S-()-metoprolol andR-(þ)-metoprolol under fasting condition. Approximately
1000 samples including the calibration, QC, volunteer samples
and ISR samples were run and analyzed during a period of 6
days and the precision and accuracy were well within the
acceptable limits. The mean pharmacokinetic parameters
obtained for the test and reference formulations are presented
in Table 7. No signiﬁcant difference was found in Tmax and t1/2
values between the enantiomers as observed previously [7].
However, the Cmax and AUC values of S-()-metoprolol were
slightly higher than those of R-(þ)-metoprolol. This observa-
tion is in line with several other reports [7,19,20]. The Cmax
P. Sharma et al.76enantiomeric ratio (S/R) of 1.19 was higher compared to the
work of Lanchote et al. [19] with identical dose strength.
However, AUC enantiomeric ratio (S/R) of 1.05 was
signiﬁcantly lower compared to 1.37 and 1.39 for studies
involving single dose of rac-metoprolol [6]. This indicates that
both the isomers are metabolized almost to the same extent in
Indian subjects and consequently have similar accumulation in
plasma. The possible reason for this difference could be the
race of subjects, gender type (body size and muscle mass),
type of food etc. However, the 90% conﬁdence interval of
individual ratio geometric mean for test/reference was within
80%–125% for Cmax, AUC0-t and AUC0-inf as shown in
Table 8. These observations conﬁrm the bioequivalence of
the test formulation with the reference product in terms of rate
and extent of absorption. Further, there was no adverse event
during the course of the study.
ISR study has now become essential to check the reprodu-
cibility and reliability of a validated bioanalytical method. TheTable 5 Relative matrix effect in different human plasma
lots for S-()-metoprolol and R-(þ)-metoprolol.
Plasma lot Slope of calibration curve
S-()-metoprolol R-(þ)-metoprolol
Lot-1 0.0059 0.0059
Lot-2 0.0058 0.0058
Lot-3 0.0057 0.0058
Lot-4 0.0058 0.0060
Lot-5 0.0058 0.0060
Lot-6 (heparinized) 0.0062 0.0061
Lot-7 (haemolysed) 0.0059 0.0057
Lot-8 (lipidemic) 0.0061 0.0061
Mean 0.0059 0.0059
7SD 0.00017 0.00015
Precision (%) 2.9 2.5
Table 6 Stability results for S-()-metoprolol and R-(þ)-metopr
Storage condition Level S-()-m
Mean s
(ng/mL
Bench top stability, 10 h HQC 39471
LQC 1.4672
Wet extract stability; 70 h, 573 1C HQC 43070
LQC 1.6271
Dry extract stability; 69 h, 20 1C HQC 43571
LQC 1.6175
Freeze-thaw stability; 5 cycles, 20 1C HQC 38070
LQC 1.3771
Freeze-thaw stability; 5 cycles, 70 1C HQC 38270
LQC 1.3970
Long term stability in plasma; 324 days, 20 1C HQC 37473
LQC 1.4172
Long term stability in plasma; 324 days, 70 1C HQC 39171
LQC 1.4576
%Change¼ Mean stability samples2Mean comparison samples
Mean comparison samples
 100.assay reproducibility expressed as % change for selected 68
samples was within 713% for both the enantiomers (Fig. 7).3.4. Comparison with reported methods
The validated method has the highest sensitivity compared to
majority of the methods developed for stereroselective analysis
of metoprolol enantiomers [7,10,12–19,21,23] and identical
with few others [11,20,22] in biological matrices. The plasma
volume for samples preparation is only 200 mL, which is
considerably less compared to all other procedures
[7,10–14,17–23] using chiral stationary phase except the work
of Liang et al. [23] on dried blood spots. Additionally, the
total chromatographic analysis time is the shortest compared
to all other methods except one report [23]. Also, the on-
column loading of metoprolol enantiomers at ULOQ level was
only 20 ng per sample injection volume, which is signiﬁcantly
lower compared to all reported procedures.4. Conclusion
The proposed LC–MS/MS method is rapid, sensitive and
rugged for the quantiﬁcation of metoprolol enantiomers in
human plasma. The assay was found to be reliable and
reproducible to support a bioequivalence study in healthy
volunteers. Absence of matrix interference is adequately
demonstrated by post-column infusion technique and by the
precision (% CV) values for the calculated slopes of calibra-
tion curves. The validated method is selective in the presence
of some commonly used medications by healthy volunteers.
The stability data have been extensively evaluated in plasma
and also in whole blood samples. A wide linear dynamic
concentration range can adequately support pharmacokinetic
applications with higher dose formulations of rac-metoprolol.olol under different conditions (n¼6).
etoprolol R-(þ)-metoprolol
tability sample
) 7SD
%
Change
Mean stability sample
(ng/mL) 7SD
%
Change
.6 1.5 39173.2 2.3
.3 2.7 1.4574.7 3.3
.9 7.5 42470.9 6.0
.2 8.0 1.5773.1 4.7
.2 8.7 42970.8 7.3
.4 7.3 1.5771.9 4.7
.7 5.0 37870.8 5.5
.7 8.7 1.3973.1 7.3
.7 4.5 37970.9 5.3
.6 7.3 1.4171.5 6.0
.9 6.5 37270.3 7.0
.8 6.1 1.4074.5 6.6
.2 2.3 38071.0 5.0
.3 3.3 1.4276.7 5.3
Fig. 6 Mean plasma concentration-time proﬁle of: (A) S-()-metoprolol and (B) R-(þ)-metoprolol after oral administration of test
(200 mg metoprolol succinate extended release tablet from an Indian Pharmaceutical Company, India) and reference (Selo-zoks, 200 mg
metoprolol succinate extended release tablet from AstraZeneca, Denmark) formulations to 14 healthy Indian subjects under fasting
conditions.
Table 7 Mean pharmacokinetic parameters of S-()-metoprolol and R-(þ)-metoprolol (Mean7SD).
Parameter S-()-metoprolol R-(þ)-metoprolol
Reference Test Reference Test
Cmax (ng/mL) 52.4173.03 49.7275.35 43.7674.81 41.0873.76
Tmax (h) 9.3674.19 10.1874.23 9.5774.44 9.0474.40
t1/2 (h) 2.5071.11 2.3670.71 2.0570.85 1.9570.67
AUC0–24 (ng h/mL) 15547188 14997151 14217186 13927193
AUC0-inf (ng h/mL) 21067397 20467397 20867417 19967396
Kel (1/h) 0.3970.07 0.3870.06 0.3170.11 0.2870.15
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Table 8 Comparison of treatment ratios and 90% CIs of natural log (Ln)-transformed parameters for S-()-metoprolol and R-
(þ)-metoprolol under fasting condition.
Parameter Ratio
(test/reference)
90% conﬁdence interval
(lower–upper)
Power Intra-subject variation,
precision (%)
S-isomer R-isomer S-isomer R-isomer S-isomer R-isomer S-isomer R-isomer
Cmax 94.8 93.9 90.8–97.2 89.1–97.2 1.000 1.000 4.3 6.1
AUC0–24 96.4 97.9 94.8–98.5 93.3–100.5 1.000 1.000 2.6 5.3
AUC0-inf 97.2 95.7 95.1–99.9 91.9–99.4 1.000 1.000 2.5 4.6
Fig. 7 Graphical representation of results for 68 incurred samples of S-()-metoprolol and R-(þ)- metoprolol.
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